A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety,
and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous
Urticaria